Stress is a fundamental part of life for all cells and organisms and dealing successfully with stress facilitates survival in cells and whole organisms. Oncogenic transformation creates substantial intrinsic cell stress (e.g. metabolic, proteotoxic, DNA damage stresses). Tumor cells respond to intrinsic stress in numerous, highly conserved ways, some of which facilitate cell survival. Tumor growth may also cause changes in the microenvironment in which malignant cells develop - changes which add additional extrinsic stress factors (e.g. inflammation, hypoxia, high interstitial fluid pressure, nutritional deprivation, low pH). Finally, anticancer therapy adds to both intrinsic cell stress and may change the tumor microenvironment, modifying those stress factors, too. Cell Stress and Biophysical Therapies (CSBT) Program members are committed to understanding the mechanisms and responses in tumor cells which help them evade anticancer therapies as well as host antitumor responses. The overall goal of the CSBT Program is to identify, understand and exploit tumor cell stress and microenvironment mechanisms, and to use this to develop novel therapies. Members share interest in the imaging and therapy potential for modalities such as light, heat and ionizing radiation energies. There are three research themes in the program and each integrates basic, translational and clinical science: 1) Understanding intrinsic cancer cell stress mechanisms, 2) Understanding stress mechanisms in the host/tumor microenvironment and 3) Protecting normal cells/tissues from therapy-induced damage. The Program is co-led by Drs. Andrei Gudkov and Elizabeth Repasky each of whom has successful and complimentary research programs that span the themes of the program. Retreats and monthly program meetings focus on basic and translational research and discussions of new collaborations and clinical trial opportunities. Since the last review, the laboratories of the CSBT members have moved into closer proximity in the newly constructed Center for Genetics and Pharmacology. The program is comprised of 20 members from 8 different RPCI departments. Current annual total peer-reviewed program funding is $S.4M, of which $2.6M is NCI, and the total extramural research funding is $6.9M. Of the 353 publications of CSBT members over the last funding cycle, 21% are intra-programmatic and 20% are inter-programmatic. Importantly, the number of high impact papers (Impact Factor>10) has significantly increased (10 to 33) while at the same time, the major goal of developing new clinical trials emerging from research developed within the CSBT Program continues to be very strong and successful.

Public Health Relevance

It is now clear that the stress response in tumors, combined with stress-induced damage to normal tissues, are significant factors in therapeutic failure and tumor regrowth/metastasis. A more complete understanding of the mechanisms whereby stress, and stress responses increase the resistance of tumor cells to death, while exposing normal tissues to significant damage, will enable identification of new factors to target for blocking the responses and will increase tumor sensitivity to therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016056-37
Application #
8738360
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-06-16
Project End
2019-04-30
Budget Start
2014-06-26
Budget End
2015-04-30
Support Year
37
Fiscal Year
2014
Total Cost
$37,715
Indirect Cost
$14,918
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
La Shu, Shin; Yang, Yunchen; Allen, Cheryl L et al. (2018) Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment. Sci Rep 8:12905
Mayor, Paul C; Eng, Kevin H; Singel, Kelly L et al. (2018) Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 141:1028-1035
Dasgupta, Subhamoy; Rajapakshe, Kimal; Zhu, Bokai et al. (2018) Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature 556:249-254
Ma, Wen Wee; Xie, Hao; Fetterly, Gerald et al. (2018) A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Am J Clin Oncol :
Zhang, Dingxiao; Tang, Dean G; Rycaj, Kiera (2018) Cancer stem cells: Regulation programs, immunological properties and immunotherapy. Semin Cancer Biol 52:94-106
Gabriel, Emmanuel; Attwood, Kristopher; Al-Sukhni, Eisar et al. (2018) Age-related rates of colorectal cancer and the factors associated with overall survival. J Gastrointest Oncol 9:96-110
Barger, Carter J; Zhang, Wa; Sharma, Ashok et al. (2018) Expression of the POTE gene family in human ovarian cancer. Sci Rep 8:17136
Chen, George L; Carpenter, Paul A; Broady, Raewyn et al. (2018) Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant 24:373-380
Eng, Kevin H; Szender, J Brian; Etter, John Lewis et al. (2018) Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study. PLoS Genet 14:e1007194
Tubbs, Anthony; Sridharan, Sriram; van Wietmarschen, Niek et al. (2018) Dual Roles of Poly(dA:dT) Tracts in Replication Initiation and Fork Collapse. Cell 174:1127-1142.e19

Showing the most recent 10 out of 1555 publications